drugset
drugset / Trial / NCT05683184

OMAR Opioid Use Disorder

NCT05683184 ↗

Phase 1 Recruiting 30 enrolled Yale University National Institute on Drug Abuse (NIDA) · collab
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.

Timeline

Start
2023-03-10
Primary completion
2026-12-15
Completion
2026-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject 11C-OMAR Diagnostic / imaging agent 740 mbq —

Indications

substance-related disorder